Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Papillomavirus Infections 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Carcinoma in Situ 1Carcinoma 1Burkitt Lymphoma 1

Interventions

Topotecan 10Etoposide 7Specimen Handling 6berzosertib 5Cisplatin 5Biopsy 5sargramostim 4Platinum 4Magnetic Resonance Spectroscopy 4Irinotecan 4Carboplatin 4trioctyl phosphine oxide 3X-Rays 3Paclitaxel 3Nivolumab 31,2-diaminocyclohexaneplatinum II citrate 3veliparib 2romidepsin 2olaparib 2cabozantinib 2aldesleukin 2Tomography, X-Ray Computed 2Temozolomide 2Sunitinib 2PM 01183 2Electrocardiography 2Depsipeptides 2Decitabine 2Cyclophosphamide 2Budesonide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Small Cell Lung Carcinoma × Ondansetron × Clear all
NCT04209595 2025-03-17

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
10 enrolled 13 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡